References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailSevere prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective study
Bruyère, Olivier ULg; Roux, Christian; Nicolet, Delphine ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 361-362

Detailed reference viewed: 16 (5 ULg)
Full Text
Peer Reviewed
See detailAssessment of joint space narrowing in knee osteoarthritis has good long-term intercentre reproducibility when read in pairs with a semi-automated device
Gensburger, Deborah; DEROISY, Rita ULg; Arlot, Monique et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 247-248

Detailed reference viewed: 20 (6 ULg)
Full Text
Peer Reviewed
See detailRadiological and clinical profil of osteoarthritic patients undergoing of total joint replacement
Neuprez, Audrey ULg; François, Garance ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 129-130

Detailed reference viewed: 25 (8 ULg)
Full Text
Peer Reviewed
See detailLong-term (3 years) reproducibility for the radiological assessment of knee osteoarthritis
DEROISY, Rita ULg; Bruyère, Olivier ULg; Gensburger, Deborah et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 219-220

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailAn economic evaluation of strontium ranelate for the treatment of male osteoporosis
Hiligsmann, Mickaël ULg; Ben Sedrine, Wafa ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 305-306

Detailed reference viewed: 25 (4 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women
Hiligsmann, Mickaël ULg; Ben Sedrine, Wafa ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 312-313

Detailed reference viewed: 27 (5 ULg)
See detailAntidépresseurs et risque fracturaire
Bruyère, Olivier ULg

Scientific conference (2012, February 24)

Detailed reference viewed: 4 (0 ULg)
Full Text
See detailQuel traitement pour les patients souffrant de lombalgie ?
Demoulin, Christophe ULg; Bruyère, Olivier ULg; Hill, J. C.

in Axxon Journal (2012)

Detailed reference viewed: 58 (16 ULg)
Full Text
Peer Reviewed
See detailAssessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)
Bruyère, Olivier ULg; Rizzoli, René; Coxam, V. et al

in Osteoporosis International (2012), 23

Health claims for food products in Europe are permitted if the nutrient has been shown to have a beneficial nutritional or physiological effect. This paper defines health claims related to bone health and ... [more ▼]

Health claims for food products in Europe are permitted if the nutrient has been shown to have a beneficial nutritional or physiological effect. This paper defines health claims related to bone health and provides guidelines for the design and the methodology of clinical studies to support claims. [less ▲]

Detailed reference viewed: 56 (28 ULg)
Full Text
Peer Reviewed
See detailRisk of nonvertebral fractures among elderly postmenopausal women using antidepressants
Rabenda, Véronique ULg; Bruyère, Olivier ULg; REGINSTER, Jean-Yves ULg

in Bone (2012), 51(4), 674-679

Objective: To examine the association between antidepressants, including TCAs, SSRIs, and miscellaneous antidepressants and the risk of nonvertebral fractures among women with osteoporosis. Materials and ... [more ▼]

Objective: To examine the association between antidepressants, including TCAs, SSRIs, and miscellaneous antidepressants and the risk of nonvertebral fractures among women with osteoporosis. Materials and methods: This study was a post-hoc analysis of pooled data from two international, phase III, randomized, placebo-controlled, double-blind studies (the Spinal Osteoporosis Therapeutic Intervention [SOTI] and TReatment Of Peripheral OSteoporosis [TROPOS]). A nested case-control study was performed in the placebo treated population. Adjusted logistic regression models were used to estimate the risk of nonvertebral fracture associated with the use of antidepressants. Results: After 3. years of follow-up, 391 nonvertebral fractures cases were identified and matched to 1955 controls. Compared with non-users of antidepressants, antidepressants use was associated with an increased risk of nonvertebral fractures (adjusted OR=1.64; 95%CI, 1.03-2.62]). Particularly, there was a 2-fold risk increase (95%CI, 1.07-3.79) of nonvertebral fracture for current users of SSRIs and a 2.1-fold risk increase for subjects who were current users of TCAs (95%CI, 1.02-4.30). Among patients categorized as recent or past users, none of the classes of antidepressants were statistically associated with increased risk of nonvertebral fracture. Conclusions: Our findings confirm that both SSRIs and TCAs increase the risk of nonvertebral fracture in current users. © 2012 Elsevier Inc. [less ▲]

Detailed reference viewed: 9 (3 ULg)
Full Text
Peer Reviewed
See detailClinically meaningful effect of strontium ranelate on knee osteoarthritis symptoms
Bruyère, Olivier ULg; Bellamy, N; Brown, J et al

in Arthritis and Rheumatism (2012), 64(S10), 110

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailAntidepressant medications and osteoporosis
Rizzoli, R; Cooper, C; Reginster, Jean-Yves ULg et al

in BONE (2012), 51

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailEffect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study
Bruyère, Olivier ULg; Zegels, Brigitte ULg; Leonori, Lorenzo et al

in Complementary Therapies in Medicine (2012), 20

Objective: Evaluation of the efficacy and safety of a food supplement made of collagen hydrolysate 1200 mg/day versus placebo during 6 months, in subjects with joint pain at the lower or upper limbs or at ... [more ▼]

Objective: Evaluation of the efficacy and safety of a food supplement made of collagen hydrolysate 1200 mg/day versus placebo during 6 months, in subjects with joint pain at the lower or upper limbs or at the lumbar spine. Design: Comparative double-blind randomized multicenter study in parallel groups. Setting: 200 patients of both genders of at least 50 years old with joint pain assessed as ≥30 mm on a visual analogical scale (VAS). Intervention: Collagen hydrolysate 1200 mg/day or placebo during 6 months. Main outcome measure: Comparison of the percentage of clinical responder between the active collagen hydrolysate group and the placebo group after 6 months of study. A responder subject was defined as a subject experiencing a clinically significant improvement (i.e. by 20% or more) in the most painful joint using the VAS score. All analyses were performed using an intent-totreat procedure. Results: At 6 months, the proportion of clinical responders to the treatment, according to VAS scores, was significantly higher in the collagen hydrolysate (CH) group 51.6%, compared to the placebo group 36.5% (p < 0.05). However, there was no significant difference between groups at 3 months (44.1% vs. 39.6%, p = 0.53). No significant difference in terms of security and tolerability was observed between the two groups. Conclusions: This study suggests that collagen hydrolysate 1200 mg/day could increase the number of clinical responders (i.e. improvement of at least 20% on the VAS) compared to placebo. More studies are needed to confirm the clinical interest of this food supplement. [less ▲]

Detailed reference viewed: 68 (26 ULg)